

KOMP²

Knockout Mouse Production & Phenotyping:

a



The NIH Common Fund


project

What we've done... Where we're going

NIH Council of Councils

September 5, 2014

Bldg 31, NIH Campus, Bethesda, MD



KOMP¹


“...a high-throughput effort to generate a comprehensive and public resource comprised of mouse embryonic stem (ES) cells containing a null mutation in 8500 mouse genes, and make them available and accessible to the entire research community...”



Impacts:

- *near complete coverage of the mouse genome*
- *mostly conditional-ready alleles expressing lacZ*
- *founded International Knockout Mouse Consortium*

How much phenotype data?

- ◆ Human genes have poor phenotype coverage (~35%)
- ◆ Mouse models available for ~35% of human genes
- ◆ All animal models and human phenotypes linked to >75% human genes.





Value-added features and benefits of KOMP²:

- *Broad, genome-wide coverage*
- *Fully validated, “bench-ready” models, available at cost*
- *Harmonized and validated phenotyping protocols and procedures*
- *Facilities transparency, ensures reliability & emphasizes
reproducibility*

Value-added features and benefits of KOMP²:

- *Sex-balanced cohorts distinguishes male and female phenotypes*
- *Generates actionable findings of long-standing value for follow-up*
- *Creates infrastructure and processes for testing preclinical models*
- *Pushes real-time, public dissemination of products and data*

KOMP²

“...a high-throughput, 5-year CF pilot project to produce and phenotype 2500 knockout mouse lines, and place all mice, data, and information into the public domain...”

Anticipated Impacts:


- *functional annotation of the mouse genome*
- *pathophysiological consequences of single gene deletion*
- *associations with human disease, development, behavior*

Nature, 2005



MPI2








IMPC


International Mouse Phenotyping Consortium



Gene selection...maximize “unknown” genes




CSD knockout-first, conditional-ready allele




Skarnes et al., *Nature* 2011

Regeneron VelociGene[®] definitive null allele




Valenzuela et al., *Nat. Biotechnol.* 2013

Production pipeline



(slide courtesy L. Nutter)

Production pipeline



Gene expression by LacZ (Adult)

- tm1b or tm1.1 (post-Cre)
- Whole mount & frozen section
- Adult HETs
 - 1 M and 1 F

Example: Mcam (Melanoma cell adhesion molecule)

- Angiogenesis, tissue lymphocytosis, organogenesis, cell-signaling



KOMP2 PHENOTYPING FINDINGS:

- No adult HOM phenotypes at $p < 0.0001$
- Ubiquitous vascular endothelium, smooth muscle (GI/GU, gall bladder)



Interpretation:

- Role beyond angiogenesis and development



Muscle



Brain



Adipose




(data, slide courtesy KOMP2-DTCC)


Gene expression by LacZ (Embryo)

18634 B6N(Cg)-Htr1b^{tm1.1(KOMP)Vlcg}/J


e12.5 embryo
Heterozygous




p56 Adult
Heterozygous




Cerebellum



Optic Nerve



Cervical Spinal Cord







Hippocampus & Ventral Striatum

(data, slide courtesy KOMP2-JAX)

Gene expression by LacZ

~80% of mutant lines show specific LacZ expression

Unique expression patterns in >20% of lines



(data, slide courtesy KOMP2-DTCC)

Adult phenotyping pipeline

Output to date



- *IMPC adult core pipelines established and operational at IMPC centers*
- *Baseline control data uploaded to Data Coordination Center (DCC)*
- *Preliminary QC'd phenotyping data on ~1200 mutant lines (IMPC)*
- *All KOMP² Centers processing ~15-16/week to complete by August 2016*

Case Study: Gene with known disease

Nbeal2 (Neurobeachin-like 2): “Grey Platelet Syndrome”

KOMP2 Phenotyping:

- Reduced platelet count
- Enlarged platelets





(slide courtesy MPI2)

Case Study: Gene with no known disease

Zfp719 (Zinc finger protein 719): no phenotypic associations in mouse or human

KOMP2 Phenotyping:

- Abnormal acoustic startle
- Elevated ABR response
- Significant hearing loss




(data courtesy KOMP2-BaSH;
Ramiro Ramirez-Solis PhD)


Case Study: Gene with unknown function

Fam151b (family with sequence similarity 151, member “B”): “uncharacterized”

Wildtype



Fam151b^{-/-}





KOMP2 Phenotyping:

- Retinal atrophy
- Reduced outer nuclear layer




photoreceptor deficit



(data, slide courtesy Harwell)



Case Study: Known gene/first mouse model

Bbs5 (Bardet-Biedl Syndrome): No previous KO model



KOMP2 Phenotyping:

- Abnormal gait
- Obesity
- Glucose metabolism




(data, slide courtesy Harwell)

Case Study: Known gene, revised mouse model

Atn1 (atrophin 1): Dentatorubral-pallidoluysian atrophy



Gait



KOMP2 Phenotyping:

- Abnormal gait
- Limb grasping
- CNS expression E12.5; ubiquitous adult

Tremors




(data, slide courtesy Harwell)

Case Study: Known gene/new phenotype

Cast (calpastatin): calpain/calpastatin system; inhibits myoblast fusion, gene expression

KOMP2 Phenotyping:

- Longbone (tibia) malformation defect



14 wks


8 wk



(data, slide courtesy KOMP2-JAX)

Case Study: Known gene/new male phenotype

Afmid (arylformamidase): liver and kidney expression, glomerulosclerosis




KOMP2 Phenotyping:

- Male-specific hyperglycemia
- Hypothalamic LacZ expression suggests endocrine function



Secondary & tertiary phenotyping by scientific interest group who confirmed a progressive diabetic phenotype not previously described in other mouse KO models of this gene.



(data, slide courtesy Harwell)

Case Study: Known gene/new female phenotype

Ccdc33 (coiled-coil domain containing 33): testis, spermatogenesis, peroxisomal protein


- KOMP2 Phenotyping:
- Increased auditory brain stem response
 - Female-specific hearing loss



Testis (male)



Pituitary (both sexes)




(data, slide courtesy KOMP2-DTCC)

Case Study: Known gene, pleiotropic effects




Rabl2 (RAS oncogene family-like 2): male infertility

KOMP2 Phenotyping:

- Polydactyly
- Increased body fat
- Impaired GTT (male)




IPGTT (blood glucose)



(data, slide courtesy KOMP2-DTCC)

Case Study: Known gene/new pleiotropic effects

Tead1 (TEA domain family member 1): notochord development, cell proliferation, survival, Sveinsson's chorioretinal atrophy/helicoid peripapillary chorioretinal degeneration



KOMP2 Phenotyping:

- A. Retinal B-scan and corresponding fundus volume intensity projection (VIP) of left eye. Faint spotting visible in fundus
- B. Frame 3 of sample in A, showing early rosettes/dysplasia on B-scan and spotting of fundus on VIP
- C. Frame 10 of sample in A showing increased rosettes/dysplasia and increased spotting

(data, slide courtesy KOMP2-BaSH;
Mary Dickinson, PhD)

Case Study: Known gene/complex phenotype

Galc (galactosylceramidase):


knockout mice: tremors, twitching, paralysis, death @ 7 wks

humans: “Krabbe Disease”, Globoid Cell Leukodystrophy

KOMP2 conditional allele enable refined study of disease mechanism

Wildtype

Galc^{-/-}



Peripheral nerve of skeletal muscle stained with Luxol fast blue

(data, slide courtesy KOMP2-DTCC)

Challenge Pipeline


Unsensitized and MCh-challenge screen:



Mutants (6F + 6M)




WT Controls (2F + 2M)




Svs2

- Seminal vesicle secretory protein 2
- GO: fertilization, sperm capacitation

Respiratory Function, Lung Development, and Airway Hyper-reactivity



Histopathology (allergic airway disease)



BAL (Inflammatory Cells, Cytokines)
 Serum Ig (OVA-specific IgE & OVA-specific IgG₁)
Sample analysis in progress

(data, slide courtesy KOMP2-DTCC)

Embryo/Subviable phenotyping pipeline

Output to date

- *IMPC pilots suggest ~30% rate of homozygous lethal knockouts*
- *KOMP2 Centers all established embryo/subviable pipeline*
- *Triage pipeline according to Bloomsbury Report, 2012:
Viability, Gross Morphology, Histopathology, 3D Imaging*
- *Data and image capture procedures per stage established*
- *Data collection and validation underway*

Embryo phenotyping pipeline

Tmem100^{tm1e.1(KOMP)Wtsi}




Transmembrane Protein 100 –
BMP/ALK1 signaling pathway

KOMP2 Phenotyping:

HOM lethal at E12.5 – lacZ in arterial endothelium, heart (arrow)

HOM viable at E9.5 – large pericardial effusion (arrow) and cardiac dsymorphology, enlargement (brightfield) and OPT (arrow)



(data, slide courtesy KOMP2-DTCC)


Subviable phenotyping pipeline

Tox3: HOM neonatal (P7) subviable


MRI (whole brain, P7)

KOMP2 Phenotyping:

Histopathology (cerebellum, P7)



Coronal sections: pink – tissue volume HOM > WT for amygdala, thalamus, pons; blue – tissue volume WT > HOM for pontine nucleus, cerebellum





DX: Marked diffuse cerebellar hypoplasia and dysplasia with vermis aplasia

(data, slide courtesy KOMP2-DTCC)


Goals

- *Provide high quality data that is freely available, in “real time”*
- *Promote availability of KOMP2 generated mice, tools, SOPs*
- *Transparent, versioned statistical analysis, fully reproducible*
- *Intuitive web portals and API for data discovery*

MPI2 Informatics: Data Flow



Stats Version



Display

www.mousephenotype.org



Data Dissemination: IMPC portal

 **IMPC**
International Mouse Phenotyping Consortium


www.mousephenotype.org

[Login](#) [Register](#)

[SEARCH](#) [ABOUT IMPC](#) [NEWS & EVENTS](#) [CONTACT](#) [MY IMPC](#)

We are building the first truly comprehensive, functional catalogue of a mammalian genome.

[Learn more](#)



The Knockout Mouse

A powerful tool for precision medicine.

[▶ Read why](#)

Search IMPC database

Enter your favorite **gene**, **phenotype**, **anatomy** or **protocol** to find IMPC data important to your research.

Or browse

[▶ new gene-phenotype associations](#)

Rare Disease Models

News and Events

March 18, 2014
[Successful IMPC Phenotyping Meeting held in San Francisco](#)

(slide courtesy MPI2)

Materials Dissemination

(since September 2012)

KOMP2 Center	Orders	
	Placed	Fulfilled
BaSH	385	99
JAX	288	189
DTCC*	575	414
Totals:	1248	702

*  UC DAVIS
KOMP Repository
KNOCKOUT MOUSE PROJECT

Responses to 2014 KOMP2 Survey

Details of Survey:

4 question “Survey Monkey” instrument

“publications, presentations, proposals, & opinions”

571 recipients of KOMP2 mice and/or germplasm

opened August 18 (closes September 15)

Results thus far:

28 responses first 24 h


Opinions

“...great program...”

“...KOMP mice...instrumental to our research given (my) small budget...”

“...without the ready-made mouse, we would not have generated the line on our own and would not be pursuing our current research line...”

“...greatly facilitated discovery...will hopefully lead to a publication and grant...”



Research Use



The Cells and Circuitry for Itch Responses in Mice

Santosh K. Mishra and Mark A. Hoon

Science **340**, 968 (2013);

DOI: 10.1126/science.1233765



Immunology:

TBKI-associated Protein in Endolysosomes (TAPE)/CC2D1A Is a Key Regulator Linking RIG-I-like Receptors to Antiviral Immunity

Kuan-Ru Chen, Chun-Hung Chang, Ching-Yu Huang, Chun-Yang Lin, Wan-Ying Lin, Yin-Chiu Lo, Chia-Yu Yang, En-Wei Hsiang, Lin-Fang Chen, Shin-Ru Shih, Ai-Li Shiau, Huan-Yao Lei, Tse-Hua Tan and Pin Ling

J. Biol. Chem. 2012; 287:32216-32221.
doi: 10.1074/jbc.C112.394346 originally published online July 25, 2012



This information is current as of March 11, 2014.

The Role of Sphingosine-1-Phosphate Transporter *Spns2* in Immune System Function

Anastasia Nijnik, Simon Clare, Christine Hale, Jing Chen, Claire Raisen, Lynda Mottram, Mark Lucas, Jeanne Estabel, Edward Ryder, Hibret Adissu, Sanger Mouse Genetics Project, Niels C. Adams, Ramiro Ramirez-Solis, Jacqueline K. White, Karen P. Steel, Gordon Dougan and Robert E. W. Hancock



FEBS Letters

journal homepage: www.FEBSLetters.org



Two non-vesicular ATP release pathways in the mouse erythrocyte membrane

Feng Qiu^a, Junjie Wang^a, David C. Spray^b, Eliana Scemes^b, Gerhard Dahl^{a,*}

genesis
The Journal of Genetics and Development

TECHNOLOGY REPORT

Troponin T3 Expression in Skeletal and Smooth Muscle Is Required for Growth and Postnatal Survival: Characterization of *Tnnt3^{tm2a(KOMP)Wtsi}* Mice

Yawen Ju,^{1,2} Jie Li,¹ Chao Xie,^{1,2} Christopher T. Ritchlin,^{1,3} Lianping Xing,^{1,2} Matthew J. Hilton,¹ and Edward M. Schwarz^{1,2*}

Launchpads

Transgenic Res (2014) 23:177–185
DOI 10.1007/s11248-013-9764-x

TECHNICAL REPORT

Rapid conversion of EUCOMM/KOMP-CSD alleles in mouse embryos using a cell-permeable Cre recombinase

Edward Ryder · Brendan Doe · Diane Gleeson · Richard Houghton · Priya Dalvi · Evelyn Grau · Bishoy Habib · Evelina Miklejewska · Stuart Newman · Debarati Sethi · Caroline Sinclair · Sapna Vyas · Hannah Wardle-Jones · Sanger Mouse Genetics Project · Joanna Bottomley · James Bussell · Antonella Galli · Jennifer Salisbury · Ramiro Ramirez-Solis

- Technology development
Zi media, Permeable Cre, “Prefect Host” blastocyst

- Leveraging NIH programs

Phenotyping Embryonic Lethal Knockout Mice (R01)
(PAR-13-231)


Eunice Kennedy Shriver National Institute of Child Health and Human Development

- Rare, Undiagnosed Disease Models

- Coordinating with other CF Projects

- Mouse “Networks” for follow-up phenotyping

- “Innovation at the edge”...annotating unannotated genes




MRC Consortium	MRC					
	Nominated Genes	Mutant lines made	Assay development	Data enquiry	Mouse line sent	Outstanding
Accelerated Drug Discovery					1	
Disorders of Bone and Cartilage					1	
Cardiovascular Trait Consortium					1	5
Developmental Disorders					5	5
Diabetes and Obesity					3	3
Vision Research Consortium					2	
Tissue Remodelling and Fibrosis					2	
Haematopoiesis						
Ion Channels					2	1
Liver Disease Consortium						
Processes of Ageing					1	2
Neuromouse					5	13
Kidney and Urogenital System					2	
Respiratory					1	3
Macrophages					2	
immune system					1	1
Total for MMN					27	33
Rest if the community					80	41


Where do we go from here?

- *“Phase 2” (2016-2021)... ‘kompleting’ the mouse genome*
 - *~6000 new mutant mouse lines over 5 years*
 - *Less costly per mutant than Phase 1*
- *Significant, fully-validated resource for research community...*
 - *reagents, tools, SOP’s, data, information, expertise*
 - *highly quality controlled (e.g., gender balance) processes*
 - *ensures reliability and reproducibility throughout*
 - *foundation of infrastructure, capacity, and capability*
- *Metabolomics profiling of select KOMP2 lines by KOMP2-BaSH*
- *Adopt CRISPR/Cas9 genome editing technology*
- *New, data-rich, intense phenotyping platforms*

CRISPR Cas9



(d)



Slide courtesy KOMP2-JAX

CRISPR Cas9

Eg: KOMP2-DTCC data

Mutation	# Genes	Mutation Confirmed (% of genes)	Efficiency per gene (by F0)
NHEJ	19	18 (95%)	10-100%
NHEJ + Point mutation by HDR	6	6 (100%)	6-71%
NHEJ + HR	3	2 (66%)	10-40%

NHEJ: non-homologous end joining; HDR: homology-directed repair; HR: homologous recombination

KOMP2 at BaSH, JAX, & DTCC:



- ✓ *NHEJ*
- ✓ *Point mutations*
- ✓ *LacZ insertion by homologous recombination*
- ✓ *Conditional mutagenesis*

Slide courtesy KOMP2-JAX, KOMP2-DTCC

CRISPR Cas9

Conventional Gene targeting

- Design and cloning
 - ES cell targeting and screening
 - Microinjection
- (4-7 months, \$9-12K)



Screen multiple litters for GLT
(Up to 6 months, \$2-3K++)

Typical success rate: 60-70%

Abort or GLT
Total cost: \$25,000+



Expansion

CRISPR mutagenesis

- Design and production of guides
- Microinjection (1 month, \$2-3K)



Screen multiple litters for GLT
(Up to 3 months, \$1K)

Abort or GLT

Total cost: ~\$5-13,000

Typical success rate: 85-95%



Expansion

***Production Savings:
~\$50% and ~50 weeks***

Refinement of the Phenotyping Pipeline

Development of Phase 2 pipeline

Subgroup 1 **Behavior**

Subgroup 2 **Metabolism & markers**

Subgroup 3 **Morphology**

Subgroup 4 **Challenges**


Subgroup 5 **Ex vivo**

Subgroup 6 **Sick mouse**

Subgroup 7 **Telemetry**

Subgroup 8 **Automated image analysis**

Subgroup 9 **Immune phenotyping**



The CF KOMP² Project...

discovering new knowledge about gene function

Acknowledgements

KOMP² Centers (David West [CHORI], Lynette Bower [UCD], Colin McKerlie, Ann Flenniken, Lauryl Nutter [TCP], Sara Wells [MRC Harwell], Steve Murray [JAX])

DCC and MPI2 (Terry Meehan)

IMPC (Steve Brown, Mark Moore)

The MONARCH Initiative (Melissa Haendel)

NIH (Colin Fletcher, Ray O'Neill, Oleg Mirochnitchenko)